8-K: 10x Genomics Settles Litigation with Bruker, Secures $68 Million and Ongoing Royalties

10x Genomics resolves all outstanding litigation with Bruker Corporation, resulting in a $68 million settlement and future royalty payments.

Summary

• 10x Genomics has entered into a settlement agreement and license agreements with Bruker Corporation, resolving all litigation between the parties.
• The settlement includes up-front nonrefundable payments totaling $68 million, paid in equal quarterly installments with interest between Q3 2025 and Q2 2026.
• 10x Genomics will also receive ongoing royalty payments related to licensed products and services through the life of the licensed patents.
• The parties will dismiss all claims with prejudice in all jurisdictions within five days of May 12, 2025.
• The original suits were filed against NanoString Technologies, which Bruker acquired assets and liabilities from in May 2024.

Sentiment

Score: 8

Explanation: The settlement is a positive development for 10x Genomics, resolving a legal dispute and providing a financial benefit. The ongoing royalties are also a positive.

Positives

• The settlement resolves all outstanding litigation with Bruker, removing uncertainty and potential legal costs.
• 10x Genomics will receive $68 million in up-front payments, providing a financial boost.
• Ongoing royalty payments will generate additional revenue for 10x Genomics.
• The dismissal of all claims with prejudice ensures that the litigation cannot be re-litigated.

Risks

• The forward-looking statements regarding the anticipated impacts of the settlement and license agreements are subject to risks and uncertainties.
• Actual outcomes and results could differ materially from these statements due to a number of factors.

Future Outlook

The company expects to receive $68 million in up-front payments and ongoing royalty payments, but actual outcomes could differ materially due to various factors.

Industry Context

The settlement resolves a significant legal dispute in the genomics industry, potentially impacting the competitive landscape for spatial biology technologies.

Stakeholder Impact

• Shareholders will likely view the settlement positively, as it resolves a legal dispute and provides a financial benefit.
• Employees may benefit from the increased financial stability of the company.

Next Steps

• The parties will dismiss all claims with prejudice in all jurisdictions within five days of May 12, 2025.
• 10x Genomics expects to receive up-front payments between Q3 2025 and Q2 2026.

Key Dates

Keywords

litigation, settlement, 10x Genomics, Bruker, royalties, patent, NanoString